GlycoNet Integrated Services awarded $10.68 million investment from the Canadian Foundation for Innovation’s Major Science Initiative Fund

GlycoNet Integrated Services awarded $10.68 million investment from the Canadian Foundation for Innovation’s Major Science Initiative Fund

Glycomics in Canada receives crucial funding boost to further life-saving research and biotechnology development.

GlycoNet startup, ABOzymes, completes seed financing round to fund development of technology to enable universal organ transplants and blood transfusions

GlycoNet startup, ABOzymes, completes seed financing round to fund development of technology to enable universal organ transplants and blood transfusions

Glycomics is an integral part of ABOzymes’ life-saving research and technology development.

GlycoNet partner company, Alectos Therapeutics, enters ground-breaking $700 million agreement with Biogen

GlycoNet partner company, Alectos Therapeutics, enters ground-breaking $700 million agreement with Biogen

This collaboration combines Alectos’ expertise in small-molecule therapeutics with Biogen’s development capabilities in movement disorders.

Molecules with anti-inflammatory, restorative properties could be key to tackling neurodegenerative disease

Molecules with anti-inflammatory, restorative properties could be key to tackling neurodegenerative disease

GlycoNet researchers are studying a group of molecules that could provide insight into treating and monitoring neurodegenerative diseases.

en_USEnglish
Scroll to Top